The complicated and labor-intensive manufacturing of novel cell and gene therapies requires efforts to improve workforce development programs for the nascent cell therapy industry broadly, and for cell manufacturing more specifically.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gottlieb, S. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. fda.gov, https://go.nature.com/31Orwue (January 2019).
Dodson, B. P. & Levine, A. D. BMC Biotechnol. 15, 70 (2015).
Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Mol. Ther. Methods Clin. Dev. 4, 92–101 (2017).
National Cell Manufacturing Consortium. Achieving Large-Scale, Cost-Effective, Reproducible Manufacturing of High-Quality Cells: A Technology Roadmap to 2025 (Nexight Group, 2016); https://cellmanufacturingusa.org/sites/default/files/NCMC_Roadmap_021816_high_res-2.pdf
Sullivan, J. As companies dump money into manufacturing, where will they find the trained workers to man the lines? Endpoints News, https://go.nature.com/3FoeEsu (June 2021).
McNiece, I. K., Wacker, K. K., Kurtzberg, J. & Warkentin, P. I. Cytotherapy 23, 886–893 (2021).
Eastman, P. Oncol. Times 41, 30–31 (2019).
Lindburg, L., Bozinovic, L. & Susek, R. Nat. Biotechnol. 37, 481–483 (2019).
Mason, J. L. et al. FASEB J. 30, 2673–2683 (2016).
Squibb B. M. New state-of-the-art cell therapy manufacturing facility under construction to expand Bristol Myers Squibb global footprint. news.bms.com, https://go.nature.com/3K1Guyh (February 2021).
Keown, A. Kite, a Gilead company, looks to expand its cell therapy Maryland operations. BioSpace, https://go.nature.com/3I0MYeS (August 2020).
Acknowledgements
This material is based upon work supported by the National Science Foundation under grant no. EEC-1648035. The authors thank A. Incorvaia for helpful discussions early in the development of this project, and members of the CMaT Supply Chain team for helpful discussions and support. Bristol Myers Squibb is a CMaT industry partner, but employees of Bristol Myers Squibb did not have any role in the conceptualization, design, data collection, analysis or preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
L.D.H. collected data in 2019, analyzed data and contributed to the first draft of the manuscript. H.L.R. collected data in 2020, analyzed data and contributed to the first draft of the manuscript. A.D.L. designed the project, oversaw data collection and development of the analysis strategy and revised and finalized the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ho, L.D., Robbins, H.L. & Levine, A.D. Assessing workforce needs for the emerging CAR-T cell therapy industry. Nat Biotechnol 40, 275–278 (2022). https://doi.org/10.1038/s41587-022-01212-6
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-022-01212-6
